The present disclosure relates to a novel anticancer pharmaceutical composition. The present disclosure achieves an anticancer effect using a compound effective in inhibiting the expression of ANO1 (TMEM16A). In addition, the present disclosure provides an ANO1 (TMEM16A) antagonist using the compound inhibiting the expression of ANO1 (TMEM16A).

The invention relates to novel deuterated compounds of Formula (I)

##STR00001## to a process for their preparation and to their use as medicament, in particular as antiviral medicament.

The invention relates to novel deuterated compounds of Formula (I)

##STR00001## to a process for their preparation and to their use as medicament, in particular as antiviral medicament.

This disclosure relates to the field of molecules having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the structure of Formula A.

##STR00001##

This disclosure relates to the field of molecules having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the structure of Formula A.

##STR00001##

Provided herein are formulations, processes, solid forms and methods of use relating to (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one.

Provided herein are formulations, processes, solid forms and methods of use relating to (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one.

Provided herein are thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV). Also provided herein are uses of these thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV), pharmaceutical compositions and formulations in the treatment of various diseases, including but not limited to diseases or disorders associated with an activated immune system (e.g., multiple sclerosis and psoriasis).

Provided herein are thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV). Also provided herein are uses of these thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV), pharmaceutical compositions and formulations in the treatment of various diseases, including but not limited to diseases or disorders associated with an activated immune system (e.g., multiple sclerosis and psoriasis).

Provided herein, inter alia, are methods and compounds for modulating Interleukin-2-inducible T-cell kinase.